RT Journal Article
SR Electronic
T1 Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.31.24311262
DO 10.1101/2024.07.31.24311262
A1 Hopkins, Rhian
A1 Young, Katherine G
A1 Thomas, Nicholas J
A1 Jones, Angus G
A1 Hattersley, Andrew T
A1 Shields, Beverley M
A1 Dennis, John M
A1 McGovern, Andrew P
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/08/01/2024.07.31.24311262.abstract
AB Objectives Diabetes secondary to a pancreatic condition (type 3c diabetes) affects 5-10% of people with diabetes, but evidence on the efficacy and tolerability of oral therapies in this group are lacking. We aimed to assess short-term treatment outcomes with oral anti-hyperglycaemic therapies in people with type 3c diabetes.Design Population-based cohort study.Setting UK primary care records (Clinical Practice Research Datalink; 2004-2020), linked hospital records.Participants 7,084 people with a pancreatic condition (acute pancreatitis, chronic pancreatitis, pancreatic cancer, haemochromatosis) preceding diabetes diagnosis (type 3c cohort) initiating an oral glucose-lowering therapy (metformin, sulphonylureas, SGLT2-inhibitors, DPP4-inhibitors, or thiazolidinediones [TZDs]), without concurrent insulin treatment. This cohort was stratified by evidence of pancreatic exocrine insufficiency [PEI] (1,167 with PEI, 5,917 without) and matched to 97,227 type 2 diabetes (T2D) controls.Main outcome measures 12-month HbA1c change and treatment discontinuation within 6 months, in the type 3c diabetes cohort compared to T2D controls.Results People with type 3c diabetes had a substantial mean HbA1c reduction with oral therapies in those with PEI (9.4 mmol/mol [95%CI 8.9 to 10.0]) and without (12.2 mmol/mol [12.0 to 12.4]). Compared to T2D controls, people with type 3c diabetes without PEI had a similar mean HbA1c reduction (0.7 mmol/mol [0.4 to 1.0] difference) and similar odds of early treatment discontinuation (Odds ratio [OR] 1.08 [0.98 to 1.19]). In contrast, people with type 3c diabetes and PEI had a lower mean HbA1c response (3.5 mmol/mol [2.9 to 4.1] lesser reduction), and greater discontinuation (OR 2.03 [1.73 to 2.36]). Results were largely consistent across type 3c subtypes and individual drug classes.Conclusions Oral anti-hyperglycaemic therapies are effective in people with type 3c diabetes, and could provide an important component of glycaemic management. However, the presence of PEI is associated with modestly reduced glycaemic response and reduced tolerability, meaning PEI could identify people that may benefit from closer monitoring after initiating oral therapy.What is already known on this topicDiabetes secondary to a pancreatic condition (type 3c diabetes) is common, affecting 5-10% of people with diabetes in Western populations.People with type 3c diabetes are commonly excluded from major diabetes drug trials, meaning there is a lack of management guidelines and evidence on the efficacy and tolerability of oral glucose-lowering therapies in this group.What this study addsOral glucose-lowering therapies are effective at treating hyperglycaemia in non-insulin treated type 3c diabetes, with largely similar responses to type 2 diabetes observed, and could provide an important component of glycaemic management.Pancreatic exocrine insufficiency is associated with modestly reduced glycaemic response and reduced tolerability.Competing Interest StatementAPM received prior research funding from Eli Lilly and Company, Pfizer, and AstraZeneca outside of the submitted work. All other authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis research was funded by the Medical Research Council (UK) (MR/N00633X/1). The funder had no role in any part of the study or in any decision about publication. RH and KGY are supported by Research England's Expanding Excellence in England (E3) fund. BMS and ATH are supported by the NIHR Exeter Clinical Research Facility. JMD is supported by a Wellcome Trust Early Career award (227070/Z/23/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the CPRD Independent Scientific Advisory Committee (eRAP protocol numbers: 22_002000).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo additional data are available from the authors although CPRD data are available by application to CPRD Independent Scientific Advisory Committee.